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Li-Fraumeni syndrome (LFS) is a rare autosomal dominant 
tumor predisposition syndrome caused by heterozygous ger-
mline mutation or deletion of the TP53 tumor suppressor 
gene on chromosome 17p13. The prevalence of deleterious 
TP53 germline mutations in humans is estimated to range 
from 1 in 5000 to 20,000 [6]. These TP53 germline altera-
tions can either be inherited across generations or arise de 
novo, of which de novo acquisition is estimated to occur in 
20% of affected patients [6]. LFS results in an increased risk 
of many different cancer types, including breast carcinoma, 
adrenocortical carcinoma, lymphoblastic leukemia, osteo-
sarcoma, and brain tumors [6]. The three brain tumor types 
most commonly associated with LFS are choroid plexus car-
cinoma, medulloblastoma, and glioma [9]. Approximately 
one-third of choroid plexus carcinomas are known to arise 
in the setting of LFS [11], whereas LFS only accounts for a 
small fraction of childhood medulloblastomas. The majority 
of medulloblastomas arising in the setting of LFS occur in 
the second decade of life and are most commonly large cell/
anaplastic tumors belonging to the SHH-activated and TP53-
mutant molecular subtype [12]. However, the histologic, Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0040 1-020-02144 -8) contains 
supplementary material, which is available to authorized users.
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molecular, and clinical features of gliomas arising in the 
setting of LFS have not been well characterized to date.
Here we performed comprehensive genomic characteriza-
tion and studied the clinicopathologic features of 14 gliomas 
arising in the setting of LFS (Table 1 and Supplementary 
Table 1). We identified that gliomas arising in the setting of 
LFS are diffuse astrocytic neoplasms that can be segregated 
into two molecular subgroups based on IDH mutation status 
that are associated with divergent clinicopathologic features 
and patient outcomes as described below (Fig. 1).  
The IDH-mutant subgroup consisted of seven tumors 
from six patients, five female and one male, with median 
age at glioma diagnosis of 23 years (range 10–28). These 
seven tumors were uniformly located in the cerebral hemi-
spheres and were all IDH-mutant diffuse astrocytomas 
lacking necrosis, microvascular proliferation, and significant 
mitotic activity. All seven tumors harbored IDH1 mutations, 
three of which were p.R132H and four of which were the 
less common variant p.R132C (Supplementary Table 2). 
Six tumors harbored biallelic TP53 inactivation due to a 
germline missense mutation accompanied by somatic loss 
of heterozygosity (four cases) or a somatic nonsense or mis-
sense mutation (two cases; Supplementary Table 3). The 
seventh tumor (patient LF-1) arose in the setting of consti-
tutional mosaicism for a damaging TP53 missense mutation 
that was acquired during post-zygotic development, with the 
glioma arising from a cell affected by the mosaicism that 
acquired a second somatic nonsense mutation inactivating 
the remaining TP53 allele (Fig. 1a). Additionally, there were 
inactivating ATRX mutations in six of the seven tumors, with 
Table 1  Clinicopathologic features of the 13 patients with gliomas arising in the setting of Li-Fraumeni syndrome
a Patient LF-2 had two spatially distinct gliomas that were synchronously resected and independently evaluated
Patient Sex Age Personal cancer hx Family cancer hx Tumor location Histology Clinical outcome Follow-up
IDH-mutant
LF-1 F 28 None None reported Cerebral hemisphere Diffuse astrocytoma Alive with progres-
sive disease
24 months
LF-2Aa F 23 Breast DCIS None reported Cerebral hemisphere Diffuse astrocytoma Died of disease 79 months
LF-2Ba 23 Cerebral hemisphere Diffuse astrocytoma Died of unrelated 
tumor
79 months
LF-3 F 22 None Unknown Cerebral hemisphere Diffuse astrocytoma Alive, no evidence of 
progression
25 months
LF-4 M 20 None Unknown Cerebral hemisphere Diffuse astrocytoma Alive, no evidence of 
progression
27 months
LF-5 F 24 None Unknown Cerebral hemisphere Diffuse astrocytoma Alive, no evidence of 
progression
23 months
LF-6 F 10 Osteosarcoma, 
multiple gliomas
Choroid plexus carci-
noma (sister)
Cerebral hemisphere Diffuse astrocytoma Alive, no evidence of 
progression
6 months
IDH-wildtype
LF-7 M 4 None None reported Thalami Glioblastoma Died of disease 2 months
LF-8 M 6 None None reported Cerebral hemisphere Glioblastoma Died of disease 12 months
LF-9 M 18 Medulloblastoma None reported Cerebellum Anaplastic astrocy-
toma
Alive, no evidence of 
progression
15 months
LF-10 M 18 None Adrenal cortical 
carcinoma (sister)
Cerebral hemisphere Anaplastic astrocy-
toma
Alive with progres-
sive disease
13 months
LF-11 F 4 None Phyllodes tumor 
(mother); osteo-
sarcoma (uncle); 
rhabdomyosarcoma 
(aunt); astrocy-
toma, colon carci-
noma, liposarcoma 
(grandfather)
Cerebral hemisphere Diffuse astrocytoma Alive, no evidence of 
progression
7 months
LF-12 M 11 Osteosarcoma Brain cancer (aunt); 
ovarian cancer 
(grandmother); 
rhabdomyosarcoma 
(uncle)
Cerebral hemisphere Anaplastic astrocy-
toma
Alive, no evidence of 
progression
8 months
LF-13 M 6 None None reported Cerebral hemisphere Glioblastoma Alive with progres-
sive disease
4 months
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an intact/wildtype ATRX gene in the youngest patient (LF-
7). This absence of ATRX loss in patient LF-7 (10 years of 
age at time of glioma diagnosis) is similar to what has been 
previously reported in sporadic IDH-mutant astrocytomas in 
teenagers which lack the ATRX inactivation that is typical 
of their IDH-mutant astrocytoma counterparts in adults [3, 
7]. Very few additional pathogenic alterations were identi-
fied beyond IDH1, TP53, and ATRX, with only one tumor 
harboring additional CIC nonsense and ZBTB20 missense 
mutations (Fig. 1c). There were few, if any, chromosomal 
copy number changes in these seven tumors (Supplemen-
tary Table 4). The median progression-free survival for these 
patients with IDH-mutant astrocytomas arising in the setting 
of LFS was 57 months (Fig. 1d and e).
The IDH-wildtype subgroup consisted of seven tumors 
from seven patients, six male and one female, with median 
age at glioma diagnosis of 6 years (range 4–18). These seven 
tumors were located in the cerebral hemispheres (five), 
thalami (one), and cerebellum (one). Histologic diagnoses 
were glioblastoma (three), anaplastic astrocytoma (three), 
and diffuse astrocytoma (one). All seven tumors lacked 
hotspot mutations involving IDH1, IDH2, H3F3A, H3F3B, 
HIST1H3B, and HIST1H3C. Instead, five of the tumors har-
bored somatic biallelic inactivation of the NF1 tumor sup-
pressor gene and one harbored multiple EGFR activating 
missense mutations (p.L861Q and p.R252P) in the absence 
of EGFR gene amplification (Supplementary Table 2). Addi-
tionally, two tumors harbored focal high-level amplification 
of the MYCN oncogene, and individual tumors also harbored 
homozygous deletion of CDKN2A/B, focal high-level ampli-
fication of CDK6 or IGF1R, an activating missense mutation 
in PTPN11, and inactivating mutations in PBRM1 or PTPRD 
(Fig. 1c). All seven tumors harbored biallelic TP53 inacti-
vation due to a germline missense mutation (five cases) or 
gene deletion (two cases) accompanied by somatic loss of 
heterozygosity in all cases (Supplementary Table 3). All of 
the six histologically high-grade astrocytomas demonstrated 
numerous chromosomal copy number aberrations, whereas 
the one IDH-wildtype low-grade diffuse astrocytoma from 
patient LF-12 that was resected after identification on sur-
veillance imaging lacked any chromosomal copy number 
changes (Supplementary Table 4). The median progression-
free survival for these patients with IDH-wildtype astrocy-
tomas arising in the setting of LFS was 5 months (Fig. 1d 
and e).
Together, these findings indicate that gliomas arising 
in the setting of Li-Fraumeni syndrome are diffuse astro-
cytic neoplasms that can be stratified into two molecular 
subgroups based on IDH status. Based on this cohort, IDH-
mutant astrocytomas arising in the setting of LFS most 
often occur in females in the second and third decades of 
life, arise supratentorially in the cerebral hemispheres, have 
low-grade histologic features, harbor co-occurring IDH and 
ATRX mutations with a paucity of other pathogenic driv-
ers, have near-diploid genomes, and are associated with 
favorable prognosis. In contrast, IDH-wildtype astrocyto-
mas arising in the setting of LFS most often occur in males 
in the first and second decades of life, arise throughout the 
neuroaxis, have high-grade histologic features, harbor fre-
quent NF1 mutations/deletions along with a plethora of other 
pathogenic drivers including MYCN amplification, have ane-
uploid genomes, and are associated with unfavorable prog-
nosis compared to their IDH-mutant counterparts. These 
IDH-wildtype astrocytomas appear to be heterogenous in 
their anatomic location and genetic drivers (in contrast to 
the homogeneity of their IDH-mutant counterparts), and 
therefore may likely represent a biologically diverse group 
of tumors.
Interestingly, the stepwise genetic progression that occurs 
in sporadic IDH-mutant astrocytomas starts with initial 
acquisition of IDH1 mutation, followed by TP53 mutation 
and then ATRX inactivation [1, 4]. This is in contrast to IDH-
mutant astrocytomas arising in the setting of LFS where 
a germline TP53 mutation is the initiating genetic driver, 
followed by somatic inactivation of the remaining TP53 
allele that occurs prior to acquisition of IDH1 mutation and 
then ATRX inactivation (inferred based on variant allele fre-
quencies, see Supplementary Table 2). Notably, our cohort 
confirms a high frequency of variant IDH1 mutations (most 
commonly p.R132C) that has been previously identified in 
LFS-associated gliomas [13]. As has recently been appreci-
ated for gliomas arising in the setting of neurofibromatosis 
type 1 [2], we speculate that gliomas arising in the setting 
of LFS may represent distinct glioma subtypes that should 
be distinguished from their sporadic counterparts for more 
informative diagnostic, prognostic, and therapeutic classifi-
cation. We suggest the terminology “IDH-mutant [or IDH-
wildtype] astrocytoma arising in the setting of Li-Fraumeni 
syndrome” along with a description of the histologic features 
(necrosis, microvascular proliferation, mitotic activity) and 
associated genetic alterations as the best integrated diagnos-
tic framework for these syndromic gliomas pending further 
investigation.
Methods
The study cohort consisted of nine patients who underwent 
surgical resection of a glioma that had been prospectively 
clinically evaluated on the UCSF500 Cancer Panel, one 
patient who underwent surgical resection of two anatomi-
cally and genetically distinct gliomas that were evaluated 
by exome sequencing on a research basis that has been 
previously reported (patient 1 from reference 4), and three 
patients (TCGA-S9-A6U1, TCGA-DB-A64S, and TCGA-
VM-A8CH) from the diffuse lower-grade glioma cohort of 
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The Cancer Genome Atlas Research Network with IDH-
mutant astrocytomas found to harbor known pathogenic 
germline TP53 mutations [1]. All of the thirteen patients 
included in this cohort were genetically confirmed to have 
LF-1, 28 y/o F, IDH-mutant diffuse astrocytoma
LF-7, 4 y/o M, IDH-wildtype glioblastoma
a
b
d
c
e
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Li-Fraumeni syndrome by identification of a known inacti-
vating/pathogenic TP53 mutation or deletion in a constitu-
tional DNA sample via paired tumor-normal sequencing or 
via germline sequencing analysis at a commercial source. 
Methodology related to tumor genomic profiling via the 
UCSF500 Cancer Panel has been previously reported [5, 
8, 10].
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Fig. 1  Clinicopathologic features of gliomas arising in the setting of 
Li-Fraumeni syndrome (LFS). a Imaging and histology from patient 
LF-1 (28-year-old woman) showing an expansile, nonenhancing, T2/
FLAIR-hyperintense mass centered in the left temporal lobe with 
histologic features of a diffuse astrocytoma that was IDH-mutant. b 
Imaging and histology from patient LF-7 (4-year-old boy) showing an 
expansile and enhancing mass involving the thalami and left lateral 
ventricle with histologic features of a glioblastoma that was IDH-
wildtype. c Oncoprint table of the clinicopathologic and molecular 
features of the 14 gliomas arising in the setting of LFS. d, e Kaplan–
Meier analysis of progression-free survival (d) and disease-specific 
survival (e) stratified by IDH mutation status for the 14 gliomas aris-
ing in the setting of LFS. p value calculated by Log-rank (Mantel–
Cox) test
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